Tags

Type your tag names separated by a space and hit enter

Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment.
J Bone Miner Res. 2010 Apr; 25(4):891-900.JB

Abstract

Strontium ranelate (SrR) is a relatively new treatment for osteoporosis. In this study we investigated its potential impact on human bone material quality in transiliac bone biopsies from postmenopausal osteoporotic women treated 3 years with calcium and vitamin D plus either 2 g SrR per day or placebo. Bone mineralization density distribution (BMDD), strontium (Sr) concentration, collagen cross-link ratio, and indentation modulus were analyzed by quantitative backscattered electron imaging, electron-induced X-ray fluorescence analysis, synchrotron radiation induced micro X-ray fluorescence elemental mapping, Fourier transform infrared imaging, and nanoindentation, respectively. The BMDD of SrR-treated patients was shifted to higher atomic numbers (Z(mean) +1.5%, p < .05 versus placebo). We observed Sr being preferentially incorporated in bone packets formed during SrR treatment up to 6% atom fraction [Sr/(Sr + Ca)] depending on the SrR serum levels of the individuals (correlation r = 0.84, p = .018). Collagen cross-link ratio was preserved in SR-treated bone. The indentation modulus was significantly decreased in younger versus older bone packets for both placebo- (-20.5%, p < .0001) and SrR-treated individuals (-24.3%, p < .001), whereas no differences were found between the treatment groups. In conclusion, our findings indicate that after SrR treatment, Sr is heterogeneously distributed in bone and preferentially present in bone packets formed during treatment. The effect of SrR on BMDD seems to be due mainly to the uptake of Sr and not to changes in bone calcium content. Taken together, these data provide evidence that the investigated bone quality determinants at tissue level were preserved in postmenopausal osteoporotic women after 3-year treatment with 2 g SrR per day plus calcium and vitamin D.

Authors+Show Affiliations

Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 4th Medical Department, Hanusch Hospital, 1140 Vienna, Austria. paul.roschger@osteologie.atNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20437609

Citation

Roschger, Paul, et al. "Bone Material Quality in Transiliac Bone Biopsies of Postmenopausal Osteoporotic Women After 3 Years of Strontium Ranelate Treatment." Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, vol. 25, no. 4, 2010, pp. 891-900.
Roschger P, Manjubala I, Zoeger N, et al. Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment. J Bone Miner Res. 2010;25(4):891-900.
Roschger, P., Manjubala, I., Zoeger, N., Meirer, F., Simon, R., Li, C., Fratzl-Zelman, N., Misof, B. M., Paschalis, E. P., Streli, C., Fratzl, P., & Klaushofer, K. (2010). Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment. Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, 25(4), 891-900. https://doi.org/10.1359/jbmr.091028
Roschger P, et al. Bone Material Quality in Transiliac Bone Biopsies of Postmenopausal Osteoporotic Women After 3 Years of Strontium Ranelate Treatment. J Bone Miner Res. 2010;25(4):891-900. PubMed PMID: 20437609.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment. AU - Roschger,Paul, AU - Manjubala,Inderchand, AU - Zoeger,Norbert, AU - Meirer,Florian, AU - Simon,Rolf, AU - Li,Chenghao, AU - Fratzl-Zelman,Nadja, AU - Misof,Barbara M, AU - Paschalis,Eleftherios P, AU - Streli,Christina, AU - Fratzl,Peter, AU - Klaushofer,Klaus, PY - 2010/5/4/entrez PY - 2010/5/4/pubmed PY - 2010/9/15/medline SP - 891 EP - 900 JF - Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research JO - J Bone Miner Res VL - 25 IS - 4 N2 - Strontium ranelate (SrR) is a relatively new treatment for osteoporosis. In this study we investigated its potential impact on human bone material quality in transiliac bone biopsies from postmenopausal osteoporotic women treated 3 years with calcium and vitamin D plus either 2 g SrR per day or placebo. Bone mineralization density distribution (BMDD), strontium (Sr) concentration, collagen cross-link ratio, and indentation modulus were analyzed by quantitative backscattered electron imaging, electron-induced X-ray fluorescence analysis, synchrotron radiation induced micro X-ray fluorescence elemental mapping, Fourier transform infrared imaging, and nanoindentation, respectively. The BMDD of SrR-treated patients was shifted to higher atomic numbers (Z(mean) +1.5%, p < .05 versus placebo). We observed Sr being preferentially incorporated in bone packets formed during SrR treatment up to 6% atom fraction [Sr/(Sr + Ca)] depending on the SrR serum levels of the individuals (correlation r = 0.84, p = .018). Collagen cross-link ratio was preserved in SR-treated bone. The indentation modulus was significantly decreased in younger versus older bone packets for both placebo- (-20.5%, p < .0001) and SrR-treated individuals (-24.3%, p < .001), whereas no differences were found between the treatment groups. In conclusion, our findings indicate that after SrR treatment, Sr is heterogeneously distributed in bone and preferentially present in bone packets formed during treatment. The effect of SrR on BMDD seems to be due mainly to the uptake of Sr and not to changes in bone calcium content. Taken together, these data provide evidence that the investigated bone quality determinants at tissue level were preserved in postmenopausal osteoporotic women after 3-year treatment with 2 g SrR per day plus calcium and vitamin D. SN - 1523-4681 UR - https://www.unboundmedicine.com/medline/citation/20437609/Bone_material_quality_in_transiliac_bone_biopsies_of_postmenopausal_osteoporotic_women_after_3_years_of_strontium_ranelate_treatment_ L2 - https://doi.org/10.1359/jbmr.091028 DB - PRIME DP - Unbound Medicine ER -